Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review
Authors:
- Rahul KanabarRKRahul Kanabar
- Jorge BarriusoJBJorge Barriuso
- Mairéad G. McNamaraMMMairéad G. McNamara
- Was MansoorWMWas Mansoor
- Richard A. HubnerRHRichard A. Hubner
- Juan W. ValleJVJuan W. Valle
- Angela LamarcaALAngela Lamarca
- 13 March 2020
- journal article
- review article
- Published by S. Karger AG in Neuroendocrinology
- Vol. 111 (4) , 354-369
Abstract
Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN). It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs. Methods: Eligible studies (identified using MEDLINE-PubMed) were those reporting data on NEN patients who had undergone any type of liver embolisation. The primary end points were best radiological response and symptomatic response; secondary end-points included progression-free survival (PFS), overall survival (OS) and toxicity. Results: Of 598 studies screened, 101 were eligible: 16 were prospective (15.8%). The eligible studies included a total of 5,545 NEN patients, with a median of 39 patients per study (range 5–214). Pooled rate of partial response was 36.6% (38.9% achieved stable disease) and 55.2% of patients had a symptomatic response to therapy when pooled data were analysed. The median PFS and OS were 18.4 months (95% CI 15.5–21.2) and 40.7 months (95% CI 35.2–46.2) respectively. The most common toxicities were found to be abdominal pain (48.8%) and nausea (48.1%). Outcome did not significantly vary depending on the type of embolisation performed. Conclusion: Liver embolisation provides adequate symptom relief for patients with carcinoid syndrome and is also able to reach partial response in a significant proportion of patients and a reasonable PFS. Quality of studies was limited, highlighting the need of further prospective studies to confirm the most suitable form of liver embolisation in NENs.Keywords
This publication has 121 references indexed in Scilit:
- Clinical and Laboratory Toxicity after Intra-Arterial Radioembolization with 90Y-Microspheres for Unresectable Liver MetastasesPLOS ONE, 2013
- Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary InjuryCardioVascular and Interventional Radiology, 2012
- Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and ComplicationsThe Oncologist, 2012
- Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beadsJournal of Hepatology, 2012
- Hepatic Arterial Embolization for the Treatment of Metastatic Neuroendocrine TumorsInternational Journal of Hepatology, 2012
- Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasisHPB, 2012
- Transarterial Chemoembolization and Selective Internal Radiation for the Treatment of Patients with Metastatic Neuroendocrine Tumors: A Comparison of Efficacy and CostThe Oncologist, 2011
- Computed Analysis of Three-Dimensional Cone-Beam Computed Tomography Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumor: A Pilot StudyCardioVascular and Interventional Radiology, 2010
- Hepatic Neuroendocrine Metastases: Chemo- or Bland Embolization?Journal of Gastrointestinal Surgery, 2008
- Die Chemoembolisation von Karzinoidmetastasen in der LeberRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 1990